Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$14.5 - $38.0 $350,900 - $919,600
-24,200 Reduced 49.59%
24,600 $934,000
Q2 2023

Aug 14, 2023

BUY
$16.96 - $27.82 $323,936 - $531,362
19,100 Added 64.31%
48,800 $1.27 Million
Q4 2022

Feb 14, 2023

SELL
$20.18 - $33.33 $278,484 - $459,954
-13,800 Reduced 31.72%
29,700 $731,000
Q3 2022

Nov 14, 2022

SELL
$11.58 - $24.73 $383,298 - $818,563
-33,100 Reduced 43.21%
43,500 $781,000
Q2 2022

Aug 11, 2022

BUY
$8.52 - $25.26 $229,188 - $679,494
26,900 Added 54.12%
76,600 $869,000
Q1 2022

May 13, 2022

SELL
$19.89 - $43.18 $15,912 - $34,544
-800 Reduced 1.58%
49,700 $1.11 Million
Q4 2021

Feb 10, 2022

BUY
$26.75 - $46.02 $1.35 Million - $2.32 Million
50,500 New
50,500 $2.21 Million

Others Institutions Holding INBX

# of Institutions
1
Shares Held
18.6K
Call Options Held
0
Put Options Held
0

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $570M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Bellevue Group Ag Portfolio

Follow Bellevue Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.